ORIGINAL ARTICLE. A Second Liver Resection Due to Recurrent Colorectal Liver Metastases. accepted as the only curative
|
|
- Asher Bates
- 6 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE A Second Liver Resection Due to Recurrent Colorectal Liver Metastases Antonio Sa Cunha, MD; Christophe Laurent, MD; Alexandre Rault, MD; Philippe Couderc, MD; Eric Rullier, MD; Jean Saric, MD Background: Repeat liver resection because of recurrent colorectal liver metastases can provide survival benefit with a low rate of complications. Design: Retrospective study. Participants: Forty patients who underwent a second hepatectomy because of liver metastases from colorectal cancer. Main Outcome Measures: Short- and long-term results of a second hepatectomy and determination of prognostic factors. Results: The postoperative mortality rate was 2.5%. The postoperative morbidity rate was not significantly different after a second hepatectomy compared with single hepatectomy (42.5% and 27.5%, respectively; P=.10). Transfusion requirement and hospital stay were comparable for both a single and a second hepatectomy. Threeand 5-year overall survival rates were 55% and 31%, respectively. Disease-free survival rates at 3 and 5 years were, respectively, 49% and 27%. The interval between first and second hepatectomies and the presence of extrahepatic disease were independently related to survival (multivariate analysis). Conclusions: A second liver resection because of recurrent liver metastases from colorectal cancer is safe and provides a survival benefit similar to that with single hepatectomy. Our analysis suggests that the benefit of treatment is limited in patients who undergo a second hepatectomy within 1 year of the first operation and in those with extrahepatic disease. Arch Surg. 2007;142(12): Author Affiliations: Department of Digestive Surgery, University Hospital of Bordeaux, Bordeaux, France. HEPATIC RESECTION IS WELL accepted as the only curative treatment for colorectal liver metastases, offering 5-year survival of 25% to 58%. 1-6 However, two-thirds of patients experience recurrence. Of these, only onethird will have recurrent metastases limited to the liver. 2,4 As improvements in surgical techniques and perioperative See Invited Critique at end of article management have enabled the reduction in mortality and morbidity associated with liver surgery, the rate of a repeat hepatectomy has increased in the last years The development of percutaneous radiofrequency ablation and the increased efficacy of systemic chemotherapy regimens should lead us to evaluate the results and the role of a repeat hepatectomy. We performed a retrospective analysis of a 15-year experience with hepatic resection of colorectal metastases to assess the feasibility, morbidity, and survival benefits in patients undergoing a second hepatectomy and to determine prognostic factors. METHODS We report the single-center experience of a second liver resection because of recurrent liver metastases at Saint André Hospital, Bordeaux, France. Patients were identified by a computer-based indexing system, and hospital medical records were retrospectively reviewed. Data analyzed included demographic information, pathologic features of primary and metastatic disease, surgical and adjuvant treatment of primary and metastatic disease, and predictors of outcome and survival. All patients who underwent a second resection of hepatic metastases were enrolled in the study. SELECTION OF PATIENTS Our criteria for a second hepatectomy were similar to those for first hepatectomy. Repeat hepatectomy was considered, in the absence of any medical contraindication to liver surgery, 1144
2 when the recurrent metastasis was technically resectable, preserving at least 30% of the liver parenchyma. Patients with extrahepatic disease (local recurrence, lung metastases, or both) that was resectable (R0 resection) were included. The preoperative evaluation included carcinoembryonic antigen; abdominal ultrasonography; computed tomography of the abdomen, pelvis, and thorax; and colonoscopy. OPERATIVE PROCEDURE The operative technique of liver resection in our unit has been described previously. 23 At laparotomy, patients underwent surgical exploration via intraoperative ultrasonography and manual palpation to confirm the extent of the hepatic and extrahepatic disease. According to the anatomical classification of the liver by Couinaud, 24 hepatectomy was considered major if 3 segments or more were removed. FOLLOW-UP Systematic postoperative follow-up included clinical examination, serum carcinoembryonic antigen assay, and abdominal ultrasonography every 3 months and chest radiographic examination and computed tomography every 6 months. Colonoscopy was performed at 1 and 3 years to exclude local recurrence of the primary tumor. STATISTICAL ANALYSIS A retrospective study of factors predictive of survival was performed including patient age and sex; site and stage of the colorectal tumor; disease-free interval between primitive tumor and the first hepatectomy; resection margin at the first hepatectomy; disease-free interval between first and second hepatectomies; presence of extrahepatic disease; number, size, and distribution of metastases; preoperative level of carcinoembryonic antigen; resection margin at the second hepatectomy; postoperative morbidity; and adjuvant chemotherapy. The overall survival was evaluated using the Kaplan-Meier method and included operative mortality. Univariate analysis was performed using the log-rank test. All variables associated with survival with P.20 at univariate analysis were considered for multivariate analysis using a Cox proportional hazards regression model. P.05 was considered significant. RESULTS Table 1. Tumor Data in Patients With Colorectal Liver Metastases Who Underwent a Single and a Second Hepatic Resection Variable Patients Who Underwent a Single Hepatectomy (n=311) Patients Who Underwent a Second Hepatectomy (n=40) P Value Tumor size.80 Mean, mm cm cm No. of tumors Lobar involvement Unilobar Bilobar Hepatectomy procedure Major Minor Operative blood transfusion No Yes Residual tumor R R Operative mortality Operative morbidity, No. (%) 93 (30) 17 (42.5).15 Duration of hospital stay, 14 (8) 17 (8).70 mean (SD), d Adjuvant chemotherapy.50 No Yes From January 1, 1985, to December 31, 2000, among 311 patients who underwent liver resection because of colorectal metastases, 140 (45%) developed liver metastases with or without extrahepatic recurrence. Fifty-six patients developed liver metastases with nonresectable extrahepatic recurrence, 38 patients had liver metastases not amenable to resection, and 6 patients had general contraindications to surgery. Thus, 40 patients (12.9%; 27 men and 13 women; mean age, 63 years [age range, years]) were eligible for a second hepatectomy. The primary carcinoma was located in the colon in 30 patients (75%) and in the rectum in 10 patients (25%). Cancer stage was T2 in 6 patients (15%), T3 in 34 patients (85%), N0 in 9 patients (22.5%), and N in 31 patients (77.5%). Liver metastases were synchronous in 18 patients (45%). The median interval between the colectomy and the first hepatectomy was 10 months (range, 0-34 months), and 70% of patients underwent hepatectomy within 1 year. At the time of the first hepatectomy, no patients had extrahepatic disease. The median interval between the first and the second hepatectomies was 15 months (range, 4-63 months) and was less than 1 year in 37.5% of patients. Adjuvant chemotherapy (intravenous fluorouracil with folinic acid, 5 days a month for 6 months) was given to 138 of 311 patients (44%) after resection of liver metastases. In the 40 patients who underwent a second hepatectomy, 27 (67.5%) received adjuvant chemotherapy after the first hepatectomy and 15 (37.5%) received adjuvant chemotherapy (intravenous fluorouracil with folinic acid, 5 days a month for 6 months) after the second hepatectomy (including 3 patients who also received chemotherapy before surgery). Five patients (12.5%) had resectable extrahepatic disease: 3 locoregional recurrences that were resected during the same laparotomy and 2 pulmonary metastases that were resected after the second hepatectomy. All 5 patients underwent R0 resection of extrahepatic disease. Characteristics of tumors in patients who underwent a single and those who underwent a second hepatectomy are given in Table 1. Solitary metastasis was present in 122 patients (40%) who underwent a single hepatectomy and in 21 patients (52.5%) at the second hepatectomy. The mean diameter of metastases was larger in the single hepatectomy group (44±26 mm) than in the second hepatectomy group (36±16 mm). One hun- 1145
3 Table 2. Postoperative Morbidity a Variable Single Hepatectomy b (n=311) Second Hepatectomy c (n=40) Pleural effusion 17 (5.5) 7 (17.5) Biliary fistula 19 (6) 6 (15) Liver failure 17 (5.5) 1 (2.5) Liver cut hemorrhage 4 (1.2) 1 (2.5) Subphrenic abscess 19 (6) 6 (15) Intestinal obstruction 2 (0.6) 1 (2.5) Peritonitis 0 1 (2.5) Abdominal wound abscess 6 (2) 3 (7.5) a Values are given as number of patients (percentage). For pleural effusion, P=.03; all other P values were not significant. b There were 113 complications in 93 patients; 20 patients had 2 complications after a single hepatectomy. c There were 26 complications in 17 patients; 9 patients had 2 complications after a second hepatectomy. Overall Survival, % Second surgery Only surgery Follow-up, mo Figure 1. Kaplan-Meier curves comparing survival after liver resection in patients who underwent a single liver resection and those who underwent a second hepatectomy. dred ninety-four patients (62%) underwent major hepatectomy in the single hepatectomy group and 11 patients (27.5%) in the second hepatectomy group (P.001). The percentage of R0 resections was not significantly different between the 2 groups: 98% in the single hepatectomy group and 87.5% in the second hepatectomy group. OPERATIVE MORTALITY AND MORBIDITY One patient (2.5%) died of peritonitis after the second hepatectomy. Transfusion of red blood cells was necessary in 49 patients (15%) in the single hepatectomy group and 6 patients (15%) in the second hepatectomy group (P =.91). Two patients underwent additional operations, 1 because of intestinal occlusion and 1 because of peritonitis that was the result of an intestinal perforation. The mean complication rate was higher but not significantly different after the second hepatectomy compared with the first hepatectomy (42.5% vs 30%) (Table 2). The mean (SD) hospital stay was not significantly different between the 2 groups (14 [10] vs 17 [8] days). OVERALL AND DISEASE-FREE SURVIVAL The 3- and 5-year overall survival rates after the second hepatectomy were 55% and 31%, respectively, with a median of 31.8 months. In comparison, overall survival in the 271 patients who underwent only 1 hepatectomy was 49% at 3 years and 34% at 5 years (Figure 1). After a median follow-up of 31 months (range, months) after the second hepatectomy, 17 patients (42.5%) are alive, of whom 13 patients (32.5%) are disease free. Twenty-three patients (57.5%) died of disease recurrence. Ten patients are alive at 5 years, and 8 of these patients have had no disease recurrence. The 3- and 5-year disease-free survival rates were 49% and 27%, respectively. Twenty-seven patients developed recurrent disease: isolated liver metastases in 12 patients, hepatic and extrahepatic recurrence in 9 patients, isolated lung metastases in 3 patients, and other extrahepatic disease in 3 patients. PROGNOSTIC FACTORS AFTER REPEAT HEPATECTOMY The results of univariate analysis of overall survival after the second hepatectomy are given in Table 3. Survival was significantly better in patients without extrahepatic disease, with an interval of more than 1 year between the first and second hepatectomies, and with R0 resection. Multivariate analysis revealed that only an interval of less than 1 year between the first and second hepatectomies (mean hazard ratio, 7.3 [95% confidence interval, ]; P=.003, Cox proportional hazards regression model) and presence of extrahepatic disease (mean hazard ratio, 3.3 [95% confidence interval, ]; P=.04, Cox proportional hazards regression model) were independent prognostic factors of poor survival (Figure 2 and Figure 3). COMMENT To our knowledge, our study is one of the largest singlecenter studies of repeat liver resection because of recurrent liver metastases (Table 4). Results of the present study show that a second hepatectomy can be performed safely and provides a 5-year survival rate of 31%. Factors associated with poor prognosis are an interval of less than 1 year between the first and second hepatectomies and the presence of extrahepatic disease. Owing to recent advances in hepatic surgery and survival benefits observed after liver resection because of colorectal metastases, the repeat hepatectomy rate has dramatically increased. In our study, 13% of patients who underwent liver resection because of colorectal metastases underwent a second operation, according to the results from specialized institutes. 8,9,13,21 Repeat liver resection is associated with increased technical difficulties related to adhesions on the raw surface of the previous hepatectomy and consistency of the liver induced by regeneration. Therefore, some authors report increased morbidity and increased risk of bleeding. 25,
4 Table 3. Univariate Analysis of Prognostic Factors for Survival After a Second Liver Resection of Colorectal Liver Metastases Mean Survival, % Variable No. of Patients No. of Deaths Survival, y 1 Year 3 Years 5 Years Overall Age, y Sex Male Female Site of primary tumor Colon Rectum Parietal extension T NR NR T Lymphatic spread N N Metastases Synchronous Metachronous Interval from resection of primary tumor, mo Type of first resection Minor Major Residual tumor R R NR Extrahepatic disease Absent Present NR NR Disease-free interval, mo Type of repeat resection Minor Major Tumor size, cm No. of tumors Preoperative ACE level, UI/mL NR Clearance of surgical margin, mm Residual tumor R R NR NR Morbidity Yes No Chemotherapy Yes No P Value a Abbreviations: ACE, angiotensin-converting enzyme; NR, data not reported. a Log-rank test. 1147
5 100 No extrahepatic disease Extrahepatic disease y <12 y Survival Rate, % Survival Rate, % Survival, y Survival, y Figure 2. Kaplan-Meier curves comparing survival after liver resection in patients with and without extrahepatic disease. Figure 3. Kaplan-Meier curves comparing survival after liver resection according to interval between the first and second hepatectomies. Table 4. Summary of Large Series of Repeat Hepatectomy in Patients With Recurrent Liver Metastases Source No. of Patients Major Hepatectomy, % Mortality Rate, % Morbidity Rate, % Median Survival, mo Survival Rate After a Repeat Hepatectomy, % 5-Year 3y 5y Survivors, No. (%) Fernandez-Trigo et al, a 168 NR NR Nordlinger et al, a 130 NR NR Adam et al, NR (14) Tuttle et al, NR (13) Yamamoto et al, (12) Muratore et al, NR NR Suzuki et al, (15) Petrowsky et al, a (15) Takahashi et al, NR NR Present series, (25) Abbreviation: NR, not reported. a Multiple-center series. Despite a high incidence of major repeat hepatectomies in our study, morbidity was similar to that reported in the literature* and not significantly different than after the first hepatectomy. In addition, the transfusion rate and hospital stay were not significantly different than those observed after the first hepatectomy. We conclude that a second hepatectomy, even major resection, can be performed safely. Our policy is to always discuss the possibility of a second hepatectomy in patients with recurrence of liver cancer, using the same selection criteria as for a first hepatectomy. Repeat hepatectomy is associated with a 5-year survival rate (31%) similar to that observed after the first hepatectomy. In addition, 8 of our patients (20%) are alive without recurrence at 5 years. The resectability rate of recurrent liver metastases is similar to that reported for the first liver metastases. This rate could be increased by associated radiofrequency ablation. 27 Radiofrequency ablation was not used in the present study. *References 7-10, 12, 13, 16, 18, 19, 21, 22. References 7-10, 12, 13, 16, 18, 19, 21, 22. In our study, 2 variables were independently associated with overall survival after the second hepatectomy because of recurrent liver metastases: an interval of less than 1 year between the first and second hepatectomies and the presence of extrahepatic disease. As in the 3 other studies that identified independent prognostic factors by multivariate analysis, 8,13,21 no tumor factor related to the primary tumor and the first hepatectomy was found in our study to be an independent prognostic factor related to the second hepatectomy. Adjuvant chemotherapy after hepatic resection of colorectal metastasis has been advocated because of the substantial risk of tumor recurrence. In our study, survival in patients who underwent a second hepatectomy was not influenced by using adjuvant chemotherapy; nevertheless, fluorouracil with folinic acid was administered. The use of new drugs (irinotecan, oxiliplatin, and targeted therapies) and the response to preoperative chemotherapy, as shown by Adam et al, 28 should improve results and aid in selection of patients who can benefit from a second hepatectomy. In our study, only 5 patients (12.5%) underwent R1 liver resection; this rate is lower than those usually reported 1148
6 (17%-25%). This small number of R1 liver resections explains why we failed to show that residual tumor is an independent prognostic factor, as reported by others. 8,13 In the present study, 3-year survival was dramatically decreased in the presence of extrahepatic disease and, therefore, is an independent prognostic factor, as after the first liver resection. 29 The few patients with extrahepatic disease (2 patients with local recurrence and 3 patients with lung metastases) does not allow us to stratify free and overall survival by site of extrahepatic disease. Resection of liver and extrahepatic disease can lead to a 5-year survival of 20%. 29 Therefore, we cannot conclude that the presence of extrahepatic disease must be considered a contraindication to a second hepatectomy. As also shown by Adam et al, 8 the present study demonstrates that 5-year survival is significantly better if there is an interval of more than 1 year between the 2 hepatectomies compared with an interval of less than 1 year. These results may suggest that chemotherapy be given before surgery to enable observation of the evolution of the recurrent disease and to aid in the selection of patients who can benefit from a second hepatectomy. In conclusion, a second hepatectomy is feasible, safe, and effective in selected patients with hepatic cancer recurrence after a first hepatectomy. In patients without extrahepatic disease and with an interval of more than 1 year between hepatectomies, 5-year survival is similar to that obtained after the first hepatectomy. Repeat hepatectomy can offer prolonged survival and is the only treatment with potential for cure. Accepted for Publication: May 26, Correspondence: Antonio Sa Cunha, MD, Department of Digestive Surgery, University Hospital of Bordeaux, Ave de Magellan, Pessac 33604, Bordeaux, France. Author Contributions: Study concept and design: Sa Cunha, Laurent, Rullier, and Saric. Acquisition of data: Sa Cunha and Couderc. Analysis and interpretation of data: Sa Cunha and Saric. Drafting of the manuscript: Sa Cunha and Couderc. Critical revision of the manuscript for important intellectual content: Sa Cunha, Laurent, Rullier, and Saric. Statistical analysis: Sa Cunha. Study supervision: Sa Cunha and Saric. Financial Disclosure: None reported. REFERENCES 1. Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery. 1986;100(2): Nordlinger B, Guiguet M, Vaillant JC, et al; Association Francaise de Chirurgie. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Cancer. 1996; 77(7): Ohlsson B, Stenram U, Tranberg KG. Resection of colorectal liver metastases: 25-year experience. World J Surg. 1998;22(3): Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3): Minagawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: longterm results. Ann Surg. 2000;231(4): Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239(6): Bozzetti F, Bignami P, Montalto F, Doci R, Gennari L. Repeated hepatic resection for recurrent metastases from colorectal cancer. Br J Surg. 1992;79(2): Adam R, Bismuth H, Castaing D, et al. Repeat hepatectomy for colorectal liver metastases. Ann Surg. 1997;225(1): Fernandez-Trigo V, Shamsa F, Aldrete J, et al; Repeat Hepatic Resection Registry. Repeat liver resections from colorectal metastasis. Cancer Treat Res. 1994; 69: Fong Y, Blumgart LH, Cohen A, Fortner J, Brennan MF. Repeat hepatic resections for metastatic colorectal cancer. Ann Surg. 1994;220(5): Jaeck D, Bachellier P, Guiguet M, et al. Survival benefit of repeat liver resection for recurrent colorectal metastases: 143 cases. Wiad Lek. 1997;50(suppl 1, pt 1): Muratore A, Polastri R, Bouzari H, Vergara V, Ferrero A, Capussotti L. Repeat hepatectomy for colorectal liver metastases: a worthwhile operation? J Surg Oncol. 2001;76(2): Petrowsky H, Gonen M, Jarnagin W, et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg. 2002;235(6): Pinson CW, Wright JK, Chapman WC, Garrard CL, Blair TK, Sawyers JL. Repeat hepatic surgery for colorectal cancer metastasis to the liver. Ann Surg. 1996; 223(6): Sugarbaker PH. Repeat hepatectomy for colorectal metastases. J Hepatobiliary Pancreat Surg. 1999;6(1): Suzuki S, Sakaguchi T, Yokoi Y, et al. Impact of repeat hepatectomy on recurrent colorectal liver metastases. Surgery. 2001;129(4): Takahashi S, Inoue K, Konishi M, Nakagouri T, Kinoshita T. Prognostic factors for poor survival after repeat hepatectomy in patients with colorectal liver metastases. Surgery. 2003;133(6): Tuttle TM, Curley SA, Roh MS. Repeat hepatic resection as effective treatment of recurrent colorectal liver metastases. Ann Surg Oncol. 1997;4(2): Vaillant JC, Balladur P, Nordlinger B, et al. Repeat liver resection for recurrent colorectal metastases. Br J Surg. 1993;80(3): Yamada H, Katoh H, Kondo S, Okushiba S, Morikawa T. Repeat hepatectomy for recurrent hepatic metastases from colorectal cancer. Hepatogastroenterology. 2001;48(39): Yamamoto J, Kosuge T, Shimada K, Yamasaki S, Moriya Y, Sugihara K. Repeat liver resection for recurrent colorectal liver metastases. Am J Surg. 1999;178 (4): Nordlinger B, Vaillant JC, Guiguet M, et al; Association Francaise de Chirurgie. Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. J Clin Oncol. 1994;12(7): Laurent C, Sa Cunha A, Couderc P, Rullier E, Saric J. Influence of postoperative morbidity on long-term survival following liver resection for colorectal metastases. Br J Surg. 2003;90(9): Couinaud C. Leading principles for controlled hepatectomies [author s transl] [in French]. Chirurgie. 1980;106(2): Aramaki M, Kawano K, Kai T, et al. Postoperative complications of repeat hepatectomy for liver metastasis from colorectal carcinoma. Hepatogastroenterology. 2000;47(32): Elias D, Lasser P, Hoang JM, et al. Repeat hepatectomy for cancer. Br J Surg. 1993;80(12): Elias D, De Baere T, Smayra T, Ouellet JF, Roche A, Lasser P. Percutaneous radiofrequency thermoablation as an alternative to surgery for treatment of liver tumour recurrence after hepatectomy. Br J Surg. 2002;89(6): Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240(6): Elias D, Ouellet JF, Bellon N, Pignon JP, Pocard M, Lasser P. Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg. 2003;90(5):
Aggressive surgery in the multimodality treatment of liver metastases from colorectal cancer
Journal of BUON 12: 209-213, 2007 2007 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Aggressive surgery in the multimodality treatment of liver metastases from colorectal cancer N.
More informationCorrespondence should be addressed to Roland Andersson,
Gastroenterology Research and Practice Volume 2012, Article ID 568214, 4 pages doi:10.1155/2012/568214 Research Article Repeated Liver Resection for Colorectal Liver Metastases: A Comparison with Primary
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationTreatment of Colorectal Liver Metastases State of the Art
Treatment of Colorectal Liver Metastases State of the Art Eddie K. Abdalla, MD, FACS Professor and Chairman of Surgery Chief of Hepatobiliary Surgery Hilton Metropolitan Palace Hotel Beirut 16 November,
More informationOutcome following hepatic resection of metastatic renal tumors: the Paul Brousse Hospital experience
HPB, 2006; 8: 100/105 REVIEW ARTICLE Outcome following hepatic resection of metastatic renal tumors: the Paul Brousse Hospital experience THOMAS A. ALOIA, RENÉ ADAM, DANIEL AZOULAY, HENRI BISMUTH & DENIS
More informationRepeated Liver Resection for Colorectal Liver Metastases: A Comparison with Primary Liver Resections concerning Perioperative and Long-Term Outcome.
Repeated Liver Resection for Colorectal Liver Metastases: A Comparison with Primary Liver Resections concerning Perioperative and Long-Term Outcome. Jönsson, Kristoffer; Gröndahl, Gerd; Salö, Martin; Tingstedt,
More informationHepatic resection for colorectal liver metastases: prospective study
Key words: Colorectal neoplasms; Hepatectomy; Survival analysis CL Liu ST Fan CM Lo WL Law IOL Ng J Wong Hong Kong Med J 2002;8:329-33 The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road,
More informationBACKGROUND: STUDY DESIGN: RESULTS: CONCLUSIONS:
Improved Survival after Resection of Liver and Lung Colorectal Metastases Compared with Liver-Only Metastases: A Study of 112 Patients with Limited Lung Metastatic Disease Antoine Brouquet, MD, Jean Nicolas
More informationTrattamento chirurgico delle lesioni epatiche secondarie difficili. Adelmo Antonucci Chirurgia Oncologica e Epato-bilio-pancreatica
Trattamento chirurgico delle lesioni epatiche secondarie difficili Adelmo Antonucci Chirurgia Oncologica e Epato-bilio-pancreatica What does it mean difficult lesions? Diagnosis Treatment Small size Unfit
More informationSECONDARIES: A PRELIMINARY REPORT
HPB Surgery, 1990, Vol. 2, pp. 69-72 Reprints available directly from the publisher Photocopying permitted by license only 1990 Harwood Academic Publishers GmbH Printed in the United Kingdom CASE REPORTS
More informationRisk factors for cancer recurrence or death within 6 months after liver resection in patients with colorectal cancer liver metastasis
ORIGINAL ARTICLE pissn 2288-6575 eissn 2288-6796 http://dx.doi.org/10.4174/astr.2016.90.5.257 Annals of Surgical Treatment and Research Risk factors for cancer recurrence or death within 6 months after
More informationMANAGEMENT OF COLORECTAL METASTASES. Robert Warren, MD. The Postgraduate Course in General Surgery March 22, /22/2011
MANAGEMENT OF COLORECTAL METASTASES Robert Warren, MD The Postgraduate Course in General Surgery March 22, 2011 Local Systemic LIVER TUMORS:THERAPEUTIC OPTIONS Hepatoma Cholangio. Neuroendo. Colorectal
More informationTumor Marker Evolution: Comparison with Imaging for Assessment of Response to Chemotherapy in Patients with Colorectal Liver Metastases
Ann Surg Oncol DOI 1.1245/s1434-9-887-5 ORIGINAL ARTICLE HEPATOBILIARY TUMORS Tumor Marker Evolution: Comparison with Imaging for Assessment of Response to Chemotherapy in with Colorectal Liver Metastases
More informationSimultaneous Liver and Colorectal Resections Are Safe for Synchronous Colorectal Liver Metastasis
Simultaneous Liver and Colorectal Resections Are Safe for Synchronous Colorectal Liver Metastasis Robert Martin, MD, Philip Paty, MD, Yuman Fong, MD, FACS, Andrew Grace, MD, Alfred Cohen, MD, FACS, Ronald
More informationProposal of a new and simple staging system of colorectal liver metastasis
PO Box 2345, Beijing 123, China World J Gastroenterol 26 November 21; 12(43): 6961-6965 World Journal of Gastroenterology ISSN 17-9327 wjg@wjgnet.com 26 The WJG Press. All rights reserved. COLORECTAL CANCER
More informationExtension of the Frontiers of Surgical Indications in the Treatment of Liver Metastases From Colorectal Cancer
ANNALS OF SURGERY Vol. 231, No. 4, 487 499 2000 Lippincott Williams & Wilkins, Inc. Extension of the Frontiers of Surgical Indications in the Treatment of Liver Metastases From Colorectal Cancer Long-Term
More informationPredictors of a True Complete Response Among Disappearing Liver Metastases From Colorectal Cancer After Chemotherapy
Original Article Predictors of a True Complete Response Among Disappearing Liver Metastases From Colorectal Cancer After Chemotherapy Rebecca C. Auer, MD 1 ; Rebekah R. White, MD 2 ; Nancy E. Kemeny, MD
More informationColon Cancer Liver Metastases: Liver-Directed Therapy
Colon Cancer Liver Metastases: Liver-Directed Therapy Shishir K. Maithel, MD FACS Assistant Professor of Surgery Division of Surgical Oncology Winship Cancer Institute Emory University August 10, 2014
More informationManagement of Colorectal Liver Metastases
Management of Colorectal Liver Metastases MM Bernon, JEJ Krige HPB Surgical Unit, Groote Schuur Hospital Department of Surgery, University of Cape Town 50% of patients with colorectal cancer develop liver
More informationCurrent Treatment of Colorectal Metastases. Dr. Thavanathan Surgical Grand Rounds February 1, 2005
Current Treatment of Colorectal Metastases Dr. Thavanathan Surgical Grand Rounds February 1, 2005 25% will have metastases at initial presentation 25-50% 50% will develop metastases later 40% of potentially
More informationSurvival Outcomes of Liver Metastasectomy in Colorectal Cancer Cases: A Single-Center Analysis in Turkey
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.13.5195 Survival after Liver Metastasectomy in Colorectal Cancer Cases in Turkey RESEARCH ARTICLE Survival Outcomes of Liver Metastasectomy in Colorectal Cancer
More informationTwo-Stage Hepatectomy: A Planned Strategy to Treat Irresectable Liver Tumors
ANNALS OF SURGERY Vol. 232, No. 6, 777 785 2000 Lippincott Williams & Wilkins, Inc. Two-Stage Hepatectomy: A Planned Strategy to Treat Irresectable Liver Tumors René Adam, MD, PhD, Alexis Laurent, MD,
More informationNomogram for prediction of prognosis in patients with initially unresectable colorectal liver metastases
Original article Nomogram for prediction of prognosis in patients with initially unresectable colorectal liver metastases K. Imai 1,2,5, M.-A. Allard 1,2,4, C. Castro Benitez 1,2,4,E.Vibert 1,3,4, A. Sa
More informationLiver surgery for colorectal liver metastases. Keith Roberts, Consultant Liver Transplant and Liver/Pancreas Surgeon University Hospitals Birmingham
Liver surgery for colorectal liver metastases Keith Roberts, Consultant Liver Transplant and Liver/Pancreas Surgeon University Hospitals Birmingham Introduction: what do we do? UHB Liver Unit: Liver resections
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationRESEARCH ARTICLE. Qian Liu, Jian-Jun Bi, Yan-Tao Tian, Qiang Feng, Zhao-Xu Zheng, Zheng Wang* Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Outcome after Simultaneous Resection of Gastric Primary Tumour and Synchronous Liver Metastases: Survival Analysis of a Single-center Experience in China Qian Liu, Jian-Jun Bi, Yan-Tao
More informationDr Adam Bartlett. General Surgeon Senior Lecturer University of Auckland Auckland City Hospital
Dr Adam Bartlett General Surgeon Senior Lecturer University of Auckland Auckland City Hospital 11:05-11:15 Hepatic Metastectomy is Associated with Improved Survival Where is everyone? Hepatic Metastectomy
More informationResection of liver limited resectable metastases Upfront, neoadjuvant and repeat hepatectomy
Resection of liver limited resectable metastases Upfront, neoadjuvant and repeat hepatectomy Dr Chan Chung Yip MBBS, M.Med(Surgery), MD, FAMS, FRCSEd Senior Consultant and Head Department of Hepatopancreatobiliary
More informationHow to deal with synchronous primary and liver metastases
How to deal with synchronous primary and liver metastases Luis Sabater Ortí MD, PhD Associate Professor University of Valencia European Board Surgical Qualification HBP (EBSQ-HPB) Department of Surgery.
More informationPulmonary Resection for Metastases from Colorectal Cancer
ORIGINAL ARTICLE Pulmonary Resection for Metastases from Colorectal Cancer Paul M. van Schaik, MD,* Ewout A. Kouwenhoven, MD, PhD,* Robert J. Bolhuis, MD,* Bonne Biesma, MD, PhD, and Koop Bosscha, MD,
More informationTreatment strategy of metastatic rectal cancer
35.Schweizerische Koloproktologie-Tagung Treatment strategy of metastatic rectal cancer Gilles Mentha University hospital of Geneva Bern, January 18th, 2014 Colorectal cancer is the third most frequent
More informationManagement of Stage IV Colorectal Cancer: Expanding the Horizon
Management of Stage IV Colorectal Cancer: Expanding the Horizon May Tee, MD, MPH and Jan Franko, MD, PhD MercyOne Surgical Group (Mercy Surgical Affiliates) GI Oncology Conference 2019 March 1, 2019 Disclosures
More informationt I Hepatic Resection for Metastatic Colorectal Adenocarcinoma: A Proposal of a Prognostic Scoring System I ~:
Hepatic Resection for Metastatic Colorectal Adenocarcinoma: A Proposal of a Prognostic Scoring System Shunzaburo Iwatsuki MD PhD FACS Igor Dvorchik phd Juan R Madariaga MD FACS J Wallis Marsh MD FACS Forrest
More informationManagement of colorectal cancer liver metastases
Management of colorectal cancer liver metastases Aliakbarian M. M.D. Assistant professor of surgery Organ Transplant & Hepatopancreatobiliary Surgeon SUBJECTS The importance of surgical resection in colorectal
More information8 Giornata Onco-ematologica Varesina
Azienda Ospedaliera Sant Antonio Abate di Gallarate 8 Giornata Onco-ematologica Varesina Le esperienze di eccellenza del DIPO di Varese Metastasi epatiche da tumore del colon-retto: terapia medica in funzione
More informationLiver resection for colorectal liver metastases in older patients
Critical Reviews in Oncology/Hematology 67 (2008) 273 278 Liver resection for colorectal liver metastases in older patients Nicola de Liguori Carino a,, Barbara L. van Leeuwen b, Paula Ghaneh a, Andrew
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationManchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases
Manchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases Date: April 2015 Date for review: April 2018 1. Principles The recognised specialist HPB MDT for Greater
More informationEstimation of the Time of Pulmonary Metastasis in Colorectal Cancer Patients with Isolated Synchronous Liver Metastasis
Jpn J Clin Oncol 2005;35(1)18 22 doi:10.1093/jjco/hyi010 Estimation of the Time of Pulmonary Metastasis in Colorectal Cancer Patients with Isolated Synchronous Liver Metastasis Sotaro Sadahiro 1, Toshiyuki
More informationSimultaneous Colorectal and Hepatic Resections for Colorectal Cancer: Postoperative and Longterm Outcomes
Simultaneous Colorectal and Hepatic Resections for Colorectal Cancer: Postoperative and Longterm Outcomes Eduardo de Santibañes, MD, FACS, Fernando Bonadeo Lassalle, MD, Lucas McCormack, MD, Juan Pekolj,
More informationPAPER. Interval Hepatic Resection of Colorectal Metastases Improves Patient Selection
PAPE Interval Hepatic esection of Colorectal Metastases Improves Patient Selection aura A. ambert, MD; Thomas A. Colacchio, MD; ichard J. Barth, Jr, MD Hypothesis: Interval reevaluation for resectability
More informationPatient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201
Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large
More informationHow to integrate surgery in the treatment of patients with liver-only metastatic disease
How to integrate surgery in the treatment of patients with liver-only metastatic disease Luis Sabater Ortí MD, PhD Associate Professor University of Valencia European Board Surgical Qualification HBP (EBSQ-HPB)
More informationThe Glasgow prognostic score is valuable for colorectal cancer with both synchronous and metachronous unresectable liver metastases
324 The Glasgow prognostic score is valuable for colorectal cancer with both synchronous and metachronous unresectable liver metastases KENEI FURUKAWA, HIROAKI SHIBA, KOICHIRO HARUKI, YUKI FUJIWARA, TOMONORI
More informationAlthough the liver is a frequent site for tumor metastases,
ORIGINAL ARTICLES Hepatic Resection for Noncolorectal Nonendocrine Liver Metastases Analysis of 1452 Patients and Development of a Prognostic Model René Adam, MD, PhD, Laurence Chiche, MD, Thomas Aloia,
More informationTechniques to Improve Resectability of Colorectal Liver Metastases Ching-Wei D. Tzeng, M.D.
Techniques to Improve Resectability of Colorectal Liver Metastases Ching-Wei D. Tzeng, M.D. Department of Surgery Grand Rounds University of Kentucky January 15, 2014 Metastatic Colorectal Cancer (CRC)
More informationSelection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus Statement
Annals of Surgical Oncology, 13(10): 1261 1268 DOI: 10.1245/s10434-006-9023-y Selection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus Statement Chusilp Charnsangavej, MD,
More informationColorectal Liver Metastases Metachronous
Colorectal Liver Metastases Metachronous Professor Rowan Parks Professor of Surgical Sciences University of Edinburgh No disclosures Natural History of Unresected Untreated Colorectal Metastases Year N
More informationManagement of Liver Metastasis from Colorectal Carcinoma. Aisha White, M.D. SUNY Downstate Division of Transplantation
Management of Liver Metastasis from Colorectal Carcinoma Aisha White, M.D. SUNY Downstate Division of Transplantation Management of Colorectal Liver Metastasis Epidemiology 25% of patients diagnosed
More informationFive-year Survival following Radiofrequency Ablation of Small, Solitary, Hepatic Colorectal Metastases
Five-year Survival following Radiofrequency Ablation of Small, Solitary, Hepatic Colorectal Metastases Alice R. Gillams, MBChB, MRCP, FRCR, and William R. Lees, MBBS, FRCR, FRCS PURPOSE: Radiofrequency
More informationIntroduction. Case Report
Case Report A patient who showed a pathologically complete response after undergoing treatment with XELOX plus bevacizumab for synchronous liver metastasis of grade H2 from sigmoid colon cancer Yasuhito
More informationPAPER. HR as high as 58% have been reported. 4-7 Analyses of outcome following HR have consistently identified prognostic factors, including
PAPER Solitary Colorectal Liver Metastasis Resection Determines Outcome Thomas A. Aloia, MD; Jean-Nicolas Vauthey, MD; Evelyne M. Loyer, MD; Dario Ribero, MD; Timothy M. Pawlik, MD, MPH; Steven H. Wei,
More informationSynchronous Hepatic Cryotherapy and Resection
HPB Surgery, 2000, Vol. 11, pp. 379-382 Reprints available directly from the publisher Photocopying permitted by license only (C) 2000 OPA (Overseas Publishers Association) N.V. Published by license under
More informationTIMOTHY M. PAWLIK, RICHARD D. SCHULICK, MICHAEL A. CHOTI
The Oncologist Hepatobiliary Expanding Criteria for Resectability of Colorectal Liver Metastases TIMOTHY M. PAWLIK,RICHARD D. SCHULICK,MICHAEL A. CHOTI Department of Surgery, Johns Hopkins University School
More informationSetting The setting was outpatient (ambulatory patients). The economic study was carried out in France.
Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer Lejeune C, Bismuth M J, Conroy T, Zanni C, Bey P,
More informationAppraisal of surgical resection of gallbladder cancer with special reference to lymph node dissection
Langenbeck s Arch Surg (2000) 385:509 514 DOI 10.1007/s004230000163 CURRENT CONCEPTS IN CLINICAL SURGERY Hiroshi Shimada Itaru Endo Yoshiro Fujii Noriyuki Kamiya Hideki Masunari Osamu Kunihiro Kuniya Tanaka
More informationOutcome after emergency surgery in patients with a free perforation caused by gastric cancer
experimental and therapeutic medicine 1: 199-203, 2010 199 Outcome after emergency surgery in patients with a free perforation caused by gastric cancer Hironori Tsujimoto 1, Shuichi Hiraki 1, Naoko Sakamoto
More informationCarcinoma del colon-retto: La Chirurgia Robotica nella Malattia Avanzata
Carcinoma del colon-retto: La Chirurgia Robotica nella Malattia Avanzata Alberto Patriti SSD Chirurgia Robotica Multidisciplinare ASL 2 Umbria Ospedale San Matteo degli Infermi Spoleto - Why MIS for Advanced
More informationRegional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies
Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies Byrne Lee, MD FACS Chief, Mixed Tumor Surgery Service City of Hope Division of Surgical Oncology September
More informationThe Surgical Management of Colorectal Metastases
11th July 2017 Bowel Cancer UK The Surgical Management of Colorectal Metastases Ben Cresswell MD(Res) FRCS Consultant HPB Surgeon The Basingstoke Hepatobiliary Unit United Kingdom Surgical Management of
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationHepatic Resection is Safe for Metachronous Hepatic Metastases from Ovarian Cancer
182 Cancer Biol Niu Med et al. 2012; Hepatic 9: 182-187 Resection doi: for 10.7497/j.issn.2095-3941.2012.03.005 Ovarian Cancer Liver Metastases Original Article Hepatic Resection is Safe for Metachronous
More informationPhysician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer
Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Gabriela M. Vargas, MD Kristin M. Sheffield, PhD, Abhishek Parmar, MD, Yimei Han, MS, Kimberly M. Brown,
More informationEvolution of Surgery: Role of the Surgeon in the Molecular and Technology Age. Yuman Fong, MD Memorial Sloan-Kettering Cancer Center Rio 2010
Evolution of Surgery: Role of the Surgeon in the Molecular and Technology Age Yuman Fong, MD Memorial Sloan-Kettering Cancer Center Rio 2010 Molecular mechanisms for cancer Prevention and screening Molecular
More informationHEPATIC ARTERIAL INFUSION OF CHEMOTHERAPY AFTER RESECTION OF HEPATIC METASTASES
HEPATIC ARTERIAL INFUSION OF CHEMOTHERAPY AFTER RESECTION OF HEPATIC METASTASES HEPATIC ARTERIAL INFUSION OF CHEMOTHERAPY AFTER RESECTION OF HEPATIC METASTASES FROM COLORECTAL CANCER NANCY KEMENY, M.D.,
More informationHEPATECTOMY. Surgical Potpourri Session. ACS NSQIP National Conference Salt Lake City 2012
HEPATECTOMY Surgical Potpourri Session ACS NSQIP National Conference Salt Lake City 2012 Pascal Fuchshuber, MD, PhD, FACS Kaiser Permanente Medical Center Walnut Creek - California Hepatic Resection Is
More informationTREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS
TREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS Anna Lepistö, MD, PhD Department of Colorectal Surgery, Abdominal Center, Helsinki University Hospital Incidence, prevalence and risk factors for peritoneal
More informationIS RESECTION OF PULMONARY AND HEPATIC METASTASES WARRANTED IN PATIENTS WITH COLORECTAL CANCER?
IS RESECTION OF PULMONARY AND HEPATIC METASTASES WARRANTED IN PATIENTS WITH COLORECTAL CANCER? Brigitta J. Robinson, MD a Thomas W. Rice, MD a Scott A. Strong, MD b Lisa A. Rybicki, MS c Eugene H. Blackstone,
More informationPre-operative assessment of patients for cytoreduction and HIPEC
Pre-operative assessment of patients for cytoreduction and HIPEC Washington Hospital Center Washington, DC, USA Ovarian Cancer Surgery New Strategies Bergamo, Italy May 5, 2011 Background Cytoreductive
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationCitation for published version (APA): Hompes, D. N. M. (2013). Advanced colorectal cancer: Exploring treatment boundaries.
UvA-DARE (Digital Academic Repository) Advanced colorectal cancer: Exploring treatment boundaries Hompes, Daphne Link to publication Citation for published version (APA): Hompes, D. N. M. (2013). Advanced
More informationRegional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies
Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies Byrne Lee, MD FACS Chief, Mixed Tumor Surgery Service City of Hope Division of Surgical Oncology September
More informationTakahito Nakagawa, MD, Toshiya Kamiyama, MD, Kazuaki Nakanishi, MD, Hideki Yokoo, MD, Hirofumi Kamachi, MD, Michiaki Matsushita, MD, Satoru Todo, MD
Pulmonary for metastases from hepatocellular carcinoma: Factors influencing prognosis Takahito Nakagawa, MD, Toshiya Kamiyama, MD, Kazuaki Nakanishi, MD, Hideki Yokoo, MD, Hirofumi Kamachi, MD, Michiaki
More informationQuality of Survival Reporting in Chemotherapy and Surgery Trials in Patients with Metastatic Colorectal Carcinoma
1389 Quality of Survival Reporting in Chemotherapy and Surgery Trials in Patients with Metastatic Colorectal Carcinoma Robert C. G. Martin, M.D. 1,2 Vedra A. Augenstein, M.D. 1,2 Charles R. Scoggins, M.D.
More informationNicolae Bacalbasa Carol Davila University Of Medicine and Pharmacy
Nicolae Bacalbasa Carol Davila University Of Medicine and Pharmacy Approximately 5% to 10% of breast cancers are metastatic at diagnosis (1) 50% of breast cancer patients will develop distant metastases
More informationSurgical Management of Pancreatic Cancer
I Congresso de Oncologia D Or July 5-6, 2013 Surgical Management of Pancreatic Cancer Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University School of Medicine, Baltimore, MD Estimated
More informationResults of CRS and HIPEC in. Colorectal PSM. and. Pseudomyxoma Peritonei
Results of CRS and HIPEC in Colorectal PSM and Pseudomyxoma Peritonei K. Van der Speeten 05/10/12 Introduction Results Morbidity & Mortality Adjuvant HIPEC Conclusions K. Van der Speeten Introduction PSM
More informationCurrent Controversies in the Surgical Management of Colorectal Cancer Metastases to the Liver
Current Controversies in the Surgical Management of Colorectal Cancer Metastases to the Liver Risa Small BA, Nir Lubezky MD and Menahem Ben-Haim MD Liver Surgery Unit, Department of Surgery B, Tel Aviv
More informationRadiation Therapy for Liver Malignancies
Outline Radiation Therapy for Liver Malignancies Albert J. Chang, M.D., Ph.D. Department of Radiation Oncology, UCSF March 23, 2014 Rationale for developing liver directed therapies Liver directed therapies
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationDownregulation of osteoprotegerin expression in metastatic colorectal carcinoma predicts recurrent metastasis and poor prognosis
/, Vol. 7, No. 48 Downregulation of osteoprotegerin expression in metastatic colorectal carcinoma predicts recurrent metastasis and poor prognosis Ahrim Moon 1,*, Sung-Im Do 2,*, Hyun-Soo Kim 3, Youn-Wha
More informationLong term survival study of de-novo metastatic breast cancers with or without primary tumor resection
Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationThe impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis
Received: 1 May 2017 Accepted: 23 May 2017 DOI: 10.1002/jso.24727 RESEARCH ARTICLE The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis
More informationResults of a French Multicentric Analysis
Peritonectomy, Perioperative and Intraoperative Intraperitoneal Chemotherapy for Carcinosis Arising from Gastric Cancer Results of a French Multicentric Analysis 17 th -19 th 2008 Report Digestive and
More informationHIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies
HIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies Crescent City Cancer Update: GI and HPB Saturday September 24, 2016 George M. Fuhrman,
More informationGreater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 5
Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 5 Contents 5. Assessment & Management of Liver Metastases 42 5.1. Metachronous
More informationThe role of hepatic artery lymph node in pancreatic adenocarcinoma: prognostic factor or a selection criterion for surgery
DOI:10.1111/hpb.12306 HPB ORIGINAL ARTICLE The role of hepatic artery lymph node in pancreatic adenocarcinoma: prognostic factor or a selection criterion for surgery Prejesh Philips, Erik Dunki-Jacobs,
More informationHEPATIC METASTASES. We can state 3 types of metastases depending on their treatment options:
HEPATIC METASTASES 1. Definition Metastasis means the spread of cancer. Cancerous cells can separate from the primary tumor and enter the bloodstream or the lymphatic system (the one that produces, stores,
More informationLaparoscopic Resection Of Colon & Rectal Cancers. R Sim Centre for Advanced Laparoscopic Surgery, TTSH
Laparoscopic Resection Of Colon & Rectal Cancers R Sim Centre for Advanced Laparoscopic Surgery, TTSH Feasibility and safety Adequacy - same radical surgery as open op. Efficacy short term benefits and
More informationSurgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London
Surgical management of HCC Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London Global distribution of HCC and staging systems WEST 1. Italy (Milan,
More informationPAPER. Initial Presentation With Stage IV Colorectal Cancer
Initial Presentation With Stage IV Colorectal Cancer How Aggressive Should We Be? PAPER Seth A. Rosen, MD; Joseph F. Buell, MD; Atsushi Yoshida, MD; Scott Kazsuba, BS; Roger Hurst, MD; Fabrizio Michelassi,
More informationIndeterminate Pulmonary Nodules in Patients with Colorectal Cancer
Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Jai Sule 1, Kah Wai Cheong 2, Stella Bee 2, Bettina Lieske 2,3 1 Dept of Cardiothoracic and Vascular Surgery, University Surgical Cluster,
More informationLiver resection for non-colorectal, non-neuroendocrine metastases: analysis of a multicenter study from Argentina
HPB, 2007; 9: 435439 ORIGINAL ARTICLE Liver resection for non-colorectal, non-neuroendocrine metastases: analysis of a multicenter study from Argentina J. LENDOIRE 1, M. MORO 2, O. ANDRIANI 3, J. GRONDONA
More informationMetastatic Liver Cancer
4 Metastatic Liver Cancer ANDREW J. SMITH, MD, FRCSC RONALD P. DEMATTEO, MD YUMAN FONG, MD, FACS LESLIE H. BLUMGART, MD, FACS, FRCS (ENG, EDIN, GLAS) The management of hepatic metastases has become more
More informationQuality Improvement for Portal Vein Embolization
Cardiovasc Intervent Radiol (2010) 33:452 456 DOI 10.1007/s00270-009-9737-x CIRSE GUIDELINES Quality Improvement for Portal Vein Embolization Alban Denys Pierre Bize Nicolas Demartines Frederic Deschamps
More informationPlanned relaparotomy following curative resection of a locally advanced gastrointestinal cancer
Planned relaparotomy following curative resection of a locally advanced gastrointestinal cancer PD Dr. med. Michel Adamina, MSc Department of Surgery Agenda Prerequisite for successful CRS HIPEC Planned
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationStaging Colorectal Cancer
Staging Colorectal Cancer CT is recommended as the initial staging scan for colorectal cancer to assess local extent of the disease and to look for metastases to the liver and/or lung Further imaging for
More informationThe Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer
Original Article The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer Chen Qiu, MD,* Wei Dong, MD,* Benhua Su, MBBS, Qi Liu, MD,* and Jiajun Du, PhD Introduction:
More information